Merck & Co., Inc. (MRK)
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
MRK's Keytruda remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
High Margins, Lower Price: Is This Merck Stock's Buying Window?
Merck (MRK) stock merits your attention. Why? Because it offers monopoly-like high margins at a discounted price.
Merck (MRK) Declines More Than Market: Some Information for Investors
Merck (MRK) closed the most recent trading day at $87.61, moving 1.34% from the previous trading session.
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
Merck: A Race Against The Keytruda Clock
Merck (MRK) is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late-stage pipeline and R&D investments offer long-term growth potential. Recent political developments reduce regulatory risks, and the company's diversified operations and pipeline help buffer near-term uncertainties.
MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Big Pharma braces for the next price cut
Drugmakers know the script by now. Washington picks a handful of blockbuster medicines, haggles with their makers, and then publishes the “maximum fair price” that Medicare will pay.
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.
Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
Merck trades at 9.09x forward earnings, far below its 23.55x historical multiple and peers, while maintaining strong profitability and a 3.99% dividend yield. Blockbuster drug Keytruda, along with oncology pipeline and R&D focus, supports long-term growth despite near-term Gardasil sales decline. Heavy reliance on Keytruda, integration of new drugs, Gardasil sales volatility, and dependence on successful clinical trials could pressure revenue if outcomes disappoint.
EMA committee recommends approval for injectable version of Merck's Keytruda
The European Medicines Agency's committee has recommended the approval for a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, the U.S. drugmaker said on Friday.
